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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of hydrocolloid wound dressings for healing pressure ulcers in people in any care setting.
B A C K G R O U N D
Description of the condition
Pressure ulcers are an internationally recognised patient safety
problem, estimated to affect 2.5 million people annually (House
2011). The development of pressure ulcers in any patient is a se-
rious complication resulting in pain, decreased quality of life and
significant expenditure of both time and money for the health-
care industry (VanGilder 2009). Also known as pressure injury,
pressure sores, decubitus ulcers, or bedsores, pressure ulcers are a
localised injury to the skin, underlying tissue, or both, usually oc-
curring over a bony prominence, as a result of pressure, or pressure
in combination with shear stress (EPUAP/NPUAP 2009).
The main factors associated with the development of pressure ul-
cers are exposure of the skin to excessive pressure, and a reduced
tolerance of the skin to pressure. Pressure is exerted on the skin,
soft tissue, muscle, and bone by the weight of an individual or a
device applied against the surface. Tissue tolerance is the ability
of the skin and its supporting structures to tolerate the effects of
pressure by distributing it (cushioning) and by the transfer of pres-
sure loads from the skin surface to the skeleton (AWMA 2012).
Tissues are capable of withstanding enormous pressures briefly,
but prolonged exposure to pressure initiates a series of events that
potentially leads to necrosis and ulceration of tissue.
Factors that increase pressure on the skin include impairments in
mobility, activity or sensory perception, because then the pressure
is not relieved by movement or changes to body position. Intrinsic
risk factors for the development of pressure ulcers include advanc-
ing age, poor nutrition, poor perfusion and oxygenation, whereas,
extrinsic risk factors include increasedmoisture, shear and friction.
Shear forces and friction aggravate the effects of pressure upon
tissue and are important components of the mechanism of injury.
The combination of pressure, shear forces, and friction causes mi-
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crocirculatory occlusion, resulting in ischemia and tissue anoxia
(lack of oxygen) and stimulation of inflammatory processes, which
may lead to necrotic cell death, and ulceration. Irreversible tissue
damage may occur in a vulnerable patient with as little as 30 min-
utes of uninterrupted pressure (Kirman 2008). In addition, exces-
sive contact of the skin to fluids impairs its barrier function, causes
maceration and an increased risk of the development of pressure
ulcers.
Global prevalence rate of pressure ulcers ranges from 8% to 30%,
depending on patient factors and treatment setting. Prevalence
surveys in European acute care settings found an overall preva-
lence of 18.1%, with individual countries reporting prevalence
of between 8.3% to 23% (Vanderwee 2007). A recent US study
estimated pressure ulcer prevalences of approximately 13.3% in
acute care settings and 29% to 30% in long-term care settings
(VanGilder 2009). Within Australia, pressure ulcer prevalence is
currently estimated at between 5% to 15% in acute care settings
and between 13% and 37% in aged care (DoH 2006). These in-
ternational studies of prevalence illustrate the extent of the burden
of all grades of pressure ulcers, however, variability in prevalence in
similar settings suggests pressure ulcers are amenable to interven-
tion, with substantial potential for improvement in patient and
financial outcomes.
A number of systems for describing the amount of tissue damage
exist, but pressure ulcers are generally graded 1, 2, 3 and 4, accord-
ing to the depth of tissue damage, with category/stage 1 being the
least severe, and category/stage 4 indicating complete tissue de-
struction (Moore 2005), as illustrated inTable 1 (EPUAP/NPUAP
2009). The majority of pressure ulcers occur on the sacrum or
heel, but they also occur frequently over the elbow, hip, ischium,
shoulder, spinous process, ankle, toe, head or face (Lahmann2006;
Shanin 2008; Vanderwee 2007).
Internationally, substantial investment has occurred over recent
decades in monitoring, preventing and treating pressure ulcers.
For example, it is estimated that the annual cost of treating pres-
sure ulcers in Australia is between AUD 300-350 million with the
cost of treating a stage 4 ulcer at nearly AUD 22, 000 (AUD)
(Graves 2005; Young 1997). The total annual cost for pressure
ulcer management in the UK has been estimated to be approxi-
mately GBP 1.4 to 2.1 billion annually. This equates to 4% of the
total UK healthcare expenditure (Bennett 2004). The main costs
incurred for the treatment and management of pressure ulcers are
due to prolonged hospitalisation and the extent of nursing care
required. The average length of acute hospital stay for a patient
with a pressure ulcer is 12 days. In comparison, the average length
of stay for patients without a pressure ulcer is 4.6 days (VanGilder
2009). Furthermore, discomfort and pain, increased time spent
in hospital, increased risk of mortality, altered body image and
reduced quality of life, together with the potential cost associated
with litigation, compounds the cost to health services and the bur-
den upon the patient with the pressure ulcer (VQC 2004).
In spite of the level of investment in prevention and monitoring of
pressure ulcers, many people continue to develop them. This is the
case particularly in acute care settings where people may present
with an increased number of high risk factors such as decreased
mobility, impaired perfusion, poor nutrition, and fluctuating pa-
tient status. Pressure ulcer treatment strategies can be costly and
complex.
Description of the intervention
Treatment of pressure ulcers is primarily two-fold involving the
relief of pressure allied with wound management. Other general
strategies include patient education, pain management, optimis-
ing circulation/perfusion, optimising nutrition and the treatment
of clinical infection (AWMA 2012). Wound management may
involve surgical or chemical debridement (removal of dead tissue)
and dressings to protect the wound and promote healing. Dress-
ings can be divided into fourmain categories, namely, basic wound
dressings, advanced wound dressings, anti-microbial dressings and
specialist dressings. Classification of a dressing depends on its pur-
pose and the key material used. Key attributes of a dressing have
been described (BNF 2010), and include:
• the ability of the dressing to absorb and contain exudate
without leakage or strike-through (saturation);
• lack of particulate contaminants left in the wound;
• thermal insulation;
• level of permeability to water and bacteria;
• avoidance of wound trauma on dressing removal;
• frequency with which the dressing needs to be changed;
• provision of pain relief;
• comfort.
The focus of this review is hydrocolloid dressings, the properties
of which are described below. However, as hydrocolloid dressings
are likely to be evaluated against one of the many wound dressings
available, a description of potential comparators has been cate-
gorised, according to the British National Formulary (BNF 2010).
These are listed alphabetically below, by their generic names and,
where possible with their corresponding trade names and man-
ufacturers. Dressing names, manufactures and distributors may
vary between countries.
Absorbent dressings are applied directly to the wound and may
be used as secondary absorbent layers in the management of
heavily exuding wounds. Examples include Primapore (Smith &
Nephew), Mepore (Mölnlycke) and absorbent cotton gauze (BP
1988).
Alginate dressings are highly absorbent fabrics/yarns that come in
the formof calcium alginate or calcium sodium alginate and can be
combined with collagen. The alginate forms a gel when in contact
with the wound surface; this can be lifted off at dressing removal,
or rinsed away with sterile saline. Bonding to a secondary viscose
pad increases absorbency. Examples include: Curasorb (Covidien),
SeaSorb (Coloplast) and Sorbsan (Unomedical).
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Capillary-action dressings consist of an absorbent core of hy-
drophilic fibres held between two low-adherent contact layers. Ex-
amples include: Advadraw (Advancis) and Vacutex (Protex).
Films - permeable film andmembrane dressings - are permeable
to water vapour and oxygen, but not to water or micro-organisms.
Examples include Tegaderm (3M) andOpsite (Smith&Nephew).
Soft polymer dressings are composed of a soft silicone polymer
held in a non-adherent layer; they are moderately absorbent. Ex-
amples include: Mepitel (Mölnlycke) and Urgotul (Urgo).
Foam dressings contain hydrophilic polyurethane foam and are
designed to absorb wound exudate and maintain a moist wound
surface. There is a variety of versions and some include additional
absorbent materials, such as viscose and acrylate fibres, or particles
of superabsorbent polyacrylate, which are silicone-coated for non-
traumatic removal. Examples include: Allevyn (Smith&Nephew),
Biatain (Coloplast) and Tegaderm (3M).
Honey-impregnated dressings contain medical-grade honey that
is purported to have antimicrobial and anti-inflammatory proper-
ties and can be used for acute or chronic wounds. It is important to
note that, when such dressings are used on patients with diabetes,
the patients should be monitored for changes in blood-glucose
concentrations. Examples include: Medihoney (Medihoney) and
Activon Tulle (Advancis).
Hydrocolloid dressings are usually composed of an absorbent
hydrocolloid matrix on a vapour-permeable film or foam backing.
Examples include: Granuflex (ConvaTec) and NU DERM (Sys-
tagenix). Fibrous alternatives have been developed that resemble
alginates and are not occlusive: Aquacel (ConvaTec).
Hydrogel dressings consist of a starch polymer and up to 96%
water. These dressings can absorb wound exudate or rehydrate a
wound depending on the wound moisture levels. They are sup-
plied in either flat sheets, an amorphous hydrogel or as beads. Ex-
amples include: ActiformCool (Activa) and Aquaflo (Covidien).
Iodine-impregnated dressings release free iodine, which is
thought to act as a wound antiseptic, when exposed to wound exu-
date. Examples include Iodoflex (Smith&Nephew) and Iodozyme
(Insense).
Low-adherence dressings and wound contact materials usually
consist of cotton pads that are placed directly in contact with the
wound. They can be non-medicated (e.g. paraffin gauze dressing)
or medicated (e.g. containing povidone iodine or chlorhexidine).
Examples include paraffin gauze dressing, BP 1993 and Xeroform
(Covidien) dressing - a non-adherent petrolatum blend with 3%
bismuth tribromophenate on fine mesh gauze.
Odour-absorbent dressings contain charcoal and are used to ab-
sorb wound odour. Often this type of wound dressing is used in
conjunction with a secondary dressing to improve absorbency. An
example is CarboFLEX (ConvaTec).
Other antimicrobial dressings are composed of a gauze or low-
adherent dressing impregnated with an ointment thought to have
antimicrobial properties. Examples include: chlorhexidine gauze
dressing (Smith&Nephew) andCutimedSorbact (BSNMedical).
Protease-modulating matrix dressings alter the activity of prote-
olytic enzymes in chronic wounds. Examples include: Promogran
(Systagenix) and Sorbion (H & R).
Silver-impregnated dressings are used to treat infected wounds,
as silver ions are thought to have antimicrobial properties. Silver
versions of most dressing types are available (e.g. silver foam, silver
hydrocolloid etc). Examples include: Acticoat (Smith &Nephew)
and Urgosorb Silver (Urgo).
The diversity of dressings available to clinicians (including varia-
tion within each type listed above)makes evidence-based decision-
making difficult when determining the treatment regime for the
patient. Some dressings are formulated with an ’active’ ingredient
such as silver that is promoted as a dressing treatment option to re-
duce infection and possibly to promote healing.With increasingly
sophisticated technology being applied to wound care, practition-
ers need to know how effective these, often expensive, dressings
are compared with more traditional, and usually less costly, dress-
ings. However, far from providing critical evaluation of dressing
types for clinical use, studies have shown wide variation in practice
and wound (pressure ulcer) care knowledge (Maylor 1997; Pieper
1995).
How the intervention might work
The principle of moist wound healing governs wound care prac-
tice today. This is optimised through the application of occlu-
sive or semi-occlusive dressings and preparation of the wound bed
(AWMA 2012). Animal experiments performed 50 years ago sug-
gested that acute wounds healed more quickly when their surface
was kept moist, rather than being left to dry and to scab (Winter
1962; Winter 1963a; Winter 1963b). Winter 1962 examined the
rate of epithelialisation in experimental wounds cut into the skin
of healthy pigs, comparing wounds with a natural scab exposed to
the air against wounds that were covered with polythene film. He
found that epithelialisation occurred more quickly in the latter.
Wounds exposed to the air lose water vapour, the upper dermis
dries and healing takes place beneath a dry scab. Covering a wound
with an occlusive dressing prevents scab formation and radically
alters the pattern of epidermal wound healing. Winter’s (1962)
research focused only on acute, superficial wounds, but the results
have been used to generate a theory of moist wound healing for
all types of wound of varying aetiologies. However, the theory of
moist wound healingmay not provide a basis for satisfactory man-
agement of every type of wound encountered. Whilst a moist en-
vironment at the wound site has been shown to aid the rate of ep-
ithelialisation in superficial wounds, excess moisture at the wound
site can cause maceration of the peri wound (surrounding) skin
(Cutting 2002). Some early studies also suggested that keeping
wounds moist might predispose them to infection (Hutchinson
1991). It is not entirely clear which type(s) of wound should be
kept moist, how much moisture is required, when it should be
applied, and in what combination with other factors it actually
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confers benefit. However, Bishop and colleagues have proposed a
general principle of moisture balance (Bishop 2003), that is, that
dressingsmust absorb exudate away from thewound surface, while
ensuring that the wound surface remains moist. Despite a plethora
of research into wound care, the optimal level of exudate to pro-
mote wound healing has yet to be established.
The principle of moist wound healing has led to the develop-
ment of several commercially available wound dressings to sup-
port optimal healing processes. These have revolutionised wound
management (Benbow 2005); products include hydrogels that re-
tain moisture in contact with the wound, hydrocolloids that ab-
sorb small amounts of excess moisture without drying the wound
bed, absorbent foams, alginates, adhesive dressings, non-adhesive
dressings and silicone-based low-adherent dressings. Hydrocolloid
dressings (the subject of this review) are composed of a layer of
sodium carboxymethylcellulose (or similar material that forms a
gel when wet) bonded onto a vapour-permeable film or foam
pad. These occlusive dressings absorb exudate whilst maintaining
a moist wound environment. Fibrous hydrocolloids are a sub-set
of dressings that are designed for use in wounds with heavy ex-
udate in lieu of alternate dressing types such as alginates (BNF
2010; Pan Pacific Clinical Guidelines 2011).
Why it is important to do this review
Pressure ulcer prevention and management is a significant burden
to all healthcare systems. It is an internationally recognised patient
safety problem and serves as a clinical indicator of the standard
of care provided. Pressure ulcers are the second most reported in-
cident that leads to patient harm in the health system, and are
a significant source of suffering for patients and their care givers
(PSC 2009; Reddy 2008). Over recent decades significant invest-
ment has been placed in strategies aimed at pressure ulcer pre-
vention. Treatment strategies for pressure ulcers can also be costly
and complex, and there is a large range of wound care products
available. Despite a growing amount of literature concerned with
wound care interventions, relatively few research studies have used
clinical trial methodology to evaluate clinical effectiveness. The
complexity of suggested interventions, and range of options avail-
able suggests that the evidence requires evaluation and presenta-
tion to the clinician to assist with effective decision making. This
review is part of a suite of reviews investigating the use of individ-
ual dressing types in the treatment of pressure ulcers. Each review
will focus on a particular dressing type. These reviews will then be
summarised in an overview of reviews which will draw together all
existing Cochrane review evidence regarding the use of dressing
treatments for pressure ulcers.
There is a plethora of wound care products available, however, the
evidence base to support use of some of these products remains
incomplete. Thus, there is a clear need to provide clinicians with a
reliable evidence base with which to make sound decisions for the
treatment of pressure ulcers, if we are to reduce their prevalence
and burden.
O B J E C T I V E S
To assess the effects of hydrocolloid wound dressings for healing
pressure ulcers in people in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and controlled clinical
trials (CCTs) that have evaluated the effects of any hydrocolloid
wound dressing compared with any other dressing-based interven-
tion for treatment of pressure ulcers of grade/category 2 or above,
irrespective of publication status or language. CCTs are quasi-ran-
domised studies where, although the trial involves testing an in-
tervention and control, concurrent enrolment and follow-up of
test intervention- and control-treated groups, the method of allo-
cation is not considered strictly random (Lefebvre 2011). Cross-
over trials will be excluded.
Types of participants
People of any age with a pressure ulcer of grade/category 2 or above
in any care setting.
Types of interventions
The primary intervention under investigation is any hydrocolloid
wound dressing used for treating pressure ulcers. We will include
any trial in which the presence or absence of a hydrocolloid dress-
ing is the only systematic difference between treatment groups.
This is likely to lead to a comparison of the effects of hydrocolloid
dressings with other dressing treatments or no dressing treatment.
Types of outcome measures
Primary outcomes
• Incidence of healed pressure ulcers (proportion of
participants in whom a pressure ulcer healed);
• time to complete healing; and
• adverse events.
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Secondary outcomes
• Reduction in ulcer size;
• cost (including measurements of resource use such as
number of dressing changes and nurse time);
• quality of life (measured using any validated tool);
• patient satisfaction/acceptability measured using any tool;
and
• ulcer recurrence.
Search methods for identification of studies
Electronic searches
We will search the following trials databases:
• the Cochrane Wounds Group Specialised Register (latest);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (latest issue);
• Ovid MEDLINE (1946 to present);
• Ovid EMBASE (1974 to present);
• EBSCO CINAHL (1982 to present).
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL) using the following exploded MeSH headings and
keywords:
#1 MeSH descriptor: [Occlusive Dressings] explode all trees
#2 MeSH descriptor: [Biological Dressings] explode all trees
#3 MeSH descriptor: [Alginates] explode all trees
#4 MeSH descriptor: [Hydrogels] explode all trees
#5 MeSH descriptor: [Silver] explode all trees
#6 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#7 MeSH descriptor: [Honey] explode all trees
#8 MeSH descriptor: [Bandages, Hydrocolloid] explode all trees
#9 (dressing* or alginate* or hydrogel* or hydrocolloid* or “foam”
or “bead” or “film” or “films” or tulle or gauze or non-adherent or
“non adherent” or silver* or honey or matrix):ti,ab,kw
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #9
#11 MeSH descriptor: [Pressure Ulcer] explode all trees
#12 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#13 (decubitus next (ulcer* or sore*)):ti,ab,kw
#14 ((bed next sore*) or bedsore):ti,ab,kw
#15 #11 or #12 or #13 or #14
#16 #10 and #15
The search strategy will be adapted to search Ovid MEDLINE,
OvidEMBASE andEBSCOCINAHL.Wewill combine theOvid
MEDLINE search with the Cochrane Highly Senstive Search
Strategy for identifying randomised trials in MEDLINE: sensitiv-
ity- and precision-maximising version (2008 revision) (Lefebvre
2011). We will combine the MEDLINE and CINAHL searches
with the trial filters developed by the Scottish Intercollegiate
Guidelines Network (SIGN 2012). The EMBASE search will be
combined with the Ovid EMBASE filter developed by the UK
Cochrane Centre (Lefebvre 2011). There will be no restrictions
on the basis of date, or language or publication.
We will search the following Ongoing Trials registers to identify
ongoing or recently completed studies:
• the metaRegister of Controlled Trials (www.controlled-
trials.com);
• the U.S. National Institutes of Health ongoing trials
register (www.clinicaltrials.gov);
• the Australian and New Zealand Clinical Trials Registry
(www.anzctr.org.au);
• the World Health Organization International Clinical Trials
Registry platform (www.who.int/trialsearch)
Searching other resources
We will search bibliographies of all retrieved and relevant publica-
tions identified by these strategies for further studies. We will con-
tact manufacturers of dressings used in the prevention of pressure
ulcers (e.g. 3M, Hollister, Kendall, ConvaTec, Smith &Nephew),
and experts in the field, to ask for information relevant to this
review.
Data collection and analysis
Selection of studies
Two review authors will independently assess titles and abstracts
of all citations retrieved by the search for relevance against the
inclusion criteria. After this initial assessment, full versions of all
potentially eligible studies will be retrieved. The same two review
authors will then independently check the full papers for eligibil-
ity. Discrepancies between review authors will be resolved through
discussion and, where required, a third independent review author
will be consulted (Higgins 2011a). A list of studies that were ex-
cluded from the review, for which full trial reports were retrieved,
and the reasons for their exclusion will be published for trans-
parency. A Preferred Reporting Items of SYstematic reviews and
Meta-Analyses (PRISMA) flowchart will also be completed.
Data extraction and management
Details from eligible studies will be extracted and summarised
using a data extraction sheet. Two review authors will extract data
independently and then perform a cross check for accuracy and
agreement. Any discrepancies will be resolved though discussion
and arbitration by a third review author, if necessary. Studies that
have been published in duplicate will only be included once. If
there are any data missing from the papers, then attempts will be
made to contact study authors to retrieve themissing information.
The following data will be extracted:
• country of origin;
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• type/grade/category of pressure ulcer;
• location of pressure ulcer;
• unit of investigation (per patient) - single injury versus
multiple injuries per patient;
• care setting;
• eligibility criteria and key baseline participant data;
• number of patients randomised to each trial arm;
• details of the dressing treatment/regimen received by each
group;
• details of any co-interventions;
• primary and secondary outcome(s) with definitions;
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group);
• source of funding.
Assessment of risk of bias in included studies
Two review authors will independently assess each eligible study
for risk of bias using the Cochrane Collaboration ‘Risk of bias as-
sessment tool’. The tool addresses six specific domains, namely se-
quence generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting and other issues which
may potentially bias the study (Higgins 2011b). A ‘Risk of bias’
table will be completed for each eligible study. A separate assess-
ment of blinding and completeness of outcome data will be con-
ducted for each outcome. Discrepancies between review authors
will be resolved through discussion. Findings will be presented
using the ‘Risk of bias’ summary figure, which presents all of the
judgements in a cross-tabulation of study by entry.We will classify
trials as being at high risk of bias if they are rated ’high’ for any
of three key criteria, namely, randomisation sequence, allocation
concealment and blinded outcome assessment.
Measures of treatment effect
For dichotomous outcomes, we will calculate risk ratio (RR) plus
95% confidence intervals (CI). For continuous outcomes, we will
calculate mean difference (MD) plus 95% confidence intervals.
We will analyse time-to-event data (e.g. time to healing) as survival
data, using the appropriate analytical method (as per theCochrane
Handbook for Systematic Reviews of Interventions version 5) (
Deeks 2011). We will not analyse time-to-event data, incorrectly
presented as continuous data, but present the data in a narrative
format in the review. Skewed data are difficult to enter into a
meta-analysis unless ’normalised’ by log transformation. If scale
data, however, have finite upper and lower limits, we will apply an
easy rule of thumb in order to test for skewness. If the standard
deviation, when doubled, is greater than the mean, it is unlikely
that the mean is the centre of the distribution and will not be
entered into the meta-analysis (Altman 1996). Where continuous
data have less obvious finite boundaries, the situation is more
problematic and may be a matter of judgement. If we find relevant
data that are skewed, wewill present this data in ’Other data’ tables.
In addition, some of our secondary outcomes may be measured
using ordinal scales. For the sake of simplicity we will assume
that these are continuous, and analyse data with the standardised
mean difference (SMD). It is also possible that different tools may
be used to measure the same outcome (e.g. quality of life). We
will collect data only from those studies where scales have been
validated and are self-reported, or completed by an independent
rater or relative (not the therapist or investigator). We will use the
standardised mean difference as the summary statistic in anymeta-
analysis of such data (Deeks 2011).
Unit of analysis issues
In this type of trial, it is likely that patients will havemore than one
pressure ulcer and trialists have commonly separately randomised
multiple wounds on a patient. As a part of the ‘Risk of bias’ assess-
ment we will record how individual pressure ulcers were studied
and analysed. This will include the grading of ulcers, location of
ulcers, number of ulcers per patient, and whether they have (in-
correctly) been treated as independent in the study, rather than ap-
plying a within-patient analysis. If the unit of analysis is the ulcer
and not the person, we will describe and address unit of analysis
issues in the text.
Dealing with missing data
If there is evidence of missing data, attempts will be made to con-
tact the study authors to request the missing information. If we
consider that data are missing at random, we will analyse the avail-
able information. If we consider that data are not missing at ran-
dom, we will assume that the missing values indicate a poor out-
come. We will perform a sensitivity analysis to assess how sensitive
the results are to reasonable changes in the assumptions that are
made. We will also address the potential impact of the missing
data on the findings of the review in the discussion section.
Assessment of heterogeneity
Both clinical and statistical heterogeneity will be considered. If
appropriate, data will be pooled using meta-analysis with RevMan
5.1 (RevMan 2011). Heterogeneity of selected studies will be as-
sessed visually and by using the chi-squared test with significance
being set at P value less than 0.10.This assesses whether observed
differences in results are compatible with chance alone. In addi-
tion, the degree of heterogeneity will be investigated by calculating
the I2 statistic (an equation combining the chi-squared statistic
relative to its degree of freedom) (Higgins 2002).
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Assessment of reporting biases
We will explore reporting bias using visual asymmetry on the fun-
nel plot which will be constructed if at least 10 studies are available
for the meta analysis of a primary outcome (Sterne 2011).
Data synthesis
Initially we will conduct a structured narrative summary of the
studies reviewed. We will enter quantitative data into RevMan 5.1
(RevMan 2011), and analyse the data using the RevMan analysis
software. For dichotomous outcomes, we will calculate RR plus
95% CI. For continuous outcomes, we will calculate MD plus
95% CI. The decision to pool data in a meta-analysis will depend
upon the availability of outcome data and assessment of between-
trial heterogeneity. If evidence of significant heterogeneity is iden-
tified (i.e. greater than 50%), potential causes will be explored,
and a random-effects approach to the analysis used, otherwise a
fixed-effect method will be used.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available we will undertake the following
subgroup analysis:
• type of setting (community, hospital, inpatient, outpatient),
and
• grade/category of ulcer.
Sensitivity analysis
We will perform a sensitivity analysis by excluding studies at high
risk of bias In this sensitivity analysis, we will only include studies
that are assessed as having a low risk of bias in all key domains,
namely adequate generation of the randomisation sequence, ad-
equate allocation concealment and blinding of outcome assessor,
for the estimates of treatment effect.
’Summary of findings’ table
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schunemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of themain outcomes using theGRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) approach
(Schunemann 2011b). The GRADE approach defines the quality
of a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the quantity of
specific interest. Quality of a body of evidence involves consider-
ation of within-trial risk of bias (methodological quality), direct-
ness of evidence, heterogeneity, precision of effect estimates and
risk of publication bias (Schunemann 2011b). We plan to present
the following outcomes in the ’Summary of findings’ tables:
• time to complete ulcer healing;
• number of ulcers healed during the trial period;
• adverse events; and
• health-related quality of life.
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A D D I T I O N A L T A B L E S
Table 1. National Pressure Ulcer Advisory Panel (NPUAP)/European Pressure Ulcer Advisory Panel (EPUAP)
classification system (2009)
Category/Stage Definition
Category/Stage 1 Intact skin with non-blanchable redness of a localised area usually over a bony prominence
Darkly pigmented skin may not have visible blanching; its colour may differ from the surrounding area
The area may be painful, firm, soft, warmer or cooler compared to adjacent tissue
May be difficult to detect in individuals with dark skin tones
May indicate “at risk” persons.
Category/Stage 2 Partial thickness loss of dermis presenting as a shallow open ulcer with a red-pink wound bed, without slough
May also present as an intact or open/ruptured serum-filled or sero-sanguinous filled blister
Presenting as a shiny or dry shallow ulcer without slough or bruising
Stage II should not be used to describe skin tears, tape burns, incontinence associated dermatitis, maceration or
excoriation
Category/Stage 3 Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle is not exposed. Slough may
be present but does not obscure the depth of tissue loss. May include undermining and tunnelling.
The depth varies according to anatomical location. The bridge of the nose, ear, occiput and malleolus do not have
subcutaneous tissue and stage III pressure ulcers (PUs) can be shallow. In contrast, areas of significant adiposity
can develop extremely deep stage III PUs.
Bone or tendon is not visible or directly palpable.
Category/Stage 4 Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present on some parts
of the wound bed
The depth of a stage IV pressure injury varies by anatomical location. The bridge of the nose, ear, occiput and
malleolus do not have subcutaneous tissue and these PUs can be shallow. Stage IV PUs can extend into muscle
and/or supporting structures (e.g. fascia, tendon or joint capsule) making osteomyelitis possible.
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Table 1. National Pressure Ulcer Advisory Panel (NPUAP)/European Pressure Ulcer Advisory Panel (EPUAP)
classification system (2009) (Continued)
Exposed bone or tendon is visible or directly palpable.
A P P E N D I C E S
Appendix 1. Risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without appropriate
safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
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Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following:
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others was unlikely to introduce bias.
High risk of bias
Any one of the following:
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others was likely to introduce bias.
Unclear
Either of the following:
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following:
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
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• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Any of the following:
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following:
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• had extreme baseline imbalance; or
• has been claimed to have been fraudulent; or
• had some other problem.
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Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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